BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18

• Press Releases

  IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

  December 11, 2025

   · 

  5 min read
• Press Releases

  Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman

  December 11, 2025

   · 

  4 min read
• Press Releases

  Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer

  December 11, 2025

   · 

  4 min read
• Press Releases

  InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China

  December 11, 2025

   · 

  5 min read
• Press Releases

  DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing

  December 11, 2025

   · 

  3 min read
• Press Releases

  Certara Appoints Jon Resnick as Chief Executive Officer

  December 11, 2025

   · 

  6 min read
• Press Releases

  ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference

  December 11, 2025

   · 

  1 min read
• Press Releases

  Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

  December 11, 2025

   · 

  11 min read
• Press Releases

  Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

  December 11, 2025

   · 

  10 min read
• Press Releases

  Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

  December 11, 2025

   · 

  7 min read